Suzuki Takahiro
Division of Hematology, Department of Medicine, Jichi Medical University.
Nihon Rinsho. 2008 Mar;66(3):563-8.
Many patients with bone marrow failure need repetitive transfusion of red blood cells and most of them finally suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat iron overload caused by blood transfusion is iron chelation therapy. But most patients have not been treated sufficiently, because optimal administration of deferoxamine, the only iron chelator available in Japan, is difficult for many reasons. Recently, a novel oral iron chelator, deferasirox has been developed, and it is expected to improve chelation therapy in Japan in the near future. In this review, I will discuss the current and future status of iron overload and iron chelation therapy in transfusion-dependent patients. I will also introduce a proposed guideline for the diagnosis and treatment of iron overload in Japan.
许多骨髓衰竭患者需要反复输注红细胞,其中大多数最终会因铁过度蓄积而出现器官功能障碍。治疗输血引起的铁过载的唯一方法是铁螯合疗法。但大多数患者未得到充分治疗,原因是日本唯一可用的铁螯合剂去铁胺的最佳给药因多种原因而困难。最近,一种新型口服铁螯合剂地拉罗司已研发出来,预计在不久的将来会改善日本的螯合疗法。在这篇综述中,我将讨论依赖输血患者中铁过载和铁螯合疗法的现状及未来发展。我还将介绍日本铁过载诊断和治疗的拟议指南。